Cargando…
Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics
Multi-receptor targeting has been proposed as a promising strategy for the development of opioid analgesics with fewer side effects. Cebranopadol and AT-121 are prototypical bifunctional ligands targeting the nociceptin/orphanin FQ peptide receptor (NOP) and µ-opioid receptor (MOP) that elicit poten...
Autores principales: | Dasgupta, Pooja, Mann, Anika, Polgar, Willma E., Reinscheid, Rainer K., Zaveri, Nurulain T., Schulz, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065038/ https://www.ncbi.nlm.nih.gov/pubmed/35504962 http://dx.doi.org/10.1038/s41598-022-11189-6 |
Ejemplares similares
-
Discovery of the First Small-Molecule Opioid Pan Antagonist with Nanomolar Affinity
at Mu, Delta, Kappa, and Nociceptin Opioid Receptors
por: Zaveri, Nurulain T., et al.
Publicado: (2015) -
Structure-Based
Virtual Screening of the Nociceptin
Receptor: Hybrid Docking
and Shape-Based Approaches for Improved Hit Identification
por: Daga, Pankaj R., et al.
Publicado: (2014) -
Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships
por: Journigan, V. Blair, et al.
Publicado: (2017) -
Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies
por: Mann, Anika, et al.
Publicado: (2020) -
In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential
por: Khroyan, Taline V., et al.
Publicado: (2017)